论文部分内容阅读
目的:随机对照观察普乐安片治疗良性前列腺增生(BPH)的临床疗效。方法:将BPH患者80例前瞻性随机分为两组,治疗组60例,给予前列康3片,3/d口服;对照组20例,给予保列治1片,口服,一日一次;疗程均为90 d。观察治疗前后BPH患者的国际前列腺症状评分(IPSS)、生活质量评分(QOL)、前列腺体积、残余尿量及最大尿流率(Qmax)的改善情况。结果:普乐安片治疗良性前列腺增生(BPH)安全有效,总有效率为93.3%。随访观察3月,能明显改善患者主客观症状。治疗组IPSS及QOL评分由治疗前平均14.4±3.8及3.1±0.6分别下降至10.0±2.7及1.7±0.6,最大尿流率由治疗前(13.2±1.9)ml/s增加至治疗后(17.5±4.7)ml/s,治疗前后比较差异均有统计学意义(P<0.05)。治疗前后残余尿量、前列腺体积及PSA变化比较无统计学意义,治疗组与对照组治疗效果比较差异无显著意义(P>0.05)。结论:普乐安片是目前治疗症状性BPH患者的理想首选药物。
Objective: To observe the clinical effect of Pule Anan tablets in the treatment of benign prostatic hyperplasia (BPH). Methods: Eighty BPH patients were prospectively divided into two groups randomly. The treatment group was 60 cases. The patients were treated with Qianliekang 3 tablets orally 3 / d. The control group was given 20 tablets. The tablets were orally administered once a day. All 90 d. To observe the improvement of IPSS, QOL, prostate volume, residual urine volume and maximal flow rate (Qmax) in BPH patients before and after treatment. Results: Pleurum treatment of benign prostatic hyperplasia (BPH) safe and effective, the total effective rate was 93.3%. Follow-up observation in March, can significantly improve the patient’s subjective and objective symptoms. The IPSS and QOL scores of the treatment group decreased from 14.4 ± 3.8 and 3.1 ± 0.6 before treatment to 10.0 ± 2.7 and 1.7 ± 0.6 respectively, and the maximum flow rate increased from 13.2 ± 1.9 ml / s to 17.5 ± 4.7) ml / s, before and after treatment were statistically significant differences (P <0.05). Residual urine volume before and after treatment, prostate volume and PSA changes were not statistically significant, the treatment group and the control group was no significant difference in the treatment effect (P> 0.05). Conclusion: Proluratamine is the ideal drug of choice for the treatment of patients with symptomatic BPH.